Strategic pipeline Hemab is a clinical-stage biotech focused on prophylactic therapeutics for bleeding and thrombotic disorders, with a plan to deliver five clinical assets by 2025. This cadence suggests recurring partnering and licensing opportunities as assets advance.

Global expansion With operations in Cambridge, MA and Copenhagen, Denmark, and plans to pursue Nasdaq IPO, Hemab is expanding its geographic reach and capital markets visibility, creating openings for international collaboration, co-development, and market access partnerships.

Targeted indications Key focus areas include Glanzmann thrombasthenia, factor VII deficiency, Bernard-Soulier Syndrome, Von Willebrand Disease, and heavy menstrual bleeding. These underserved markets present high-value clinical collaboration and revenue potential for novel prophylactic antibodies.

Funding momentum Recent oversubscribed Series C totaling about $157M and ongoing Fast Track/Orphan Drug designations position Hemab as well-funded to partner on early-stage assets, making them receptive to strategic alliances, joint ventures, and out-licensing agreements.

Clinical momentum Active presentations at ISTH 2026 and data on HMB-002 and HMB-003 indicate a validated growth trajectory and near-term clinical milestones, offering sales teams opportunities to align with trials, investigator-initiated studies, and repository access for collaboration.